Azafaros B.V. aims at developing new therapeutic agents for the treatment of rare metabolic disorders
Discover moreAzafaros is focussed on the treatment of rare metabolic disorders.
The company aims at developing therapeutic agents for the treatment of rare metabolic disorders
such as lysosomal storage disorders through oral administration of azasugar compounds. These
novel, very promising agents were discovered by Professor Hans Aerts and Professor Hermen
Overkleeft at Amsterdam UMC and Leiden University, and are exclusively licensed to Azafaros.
Rare metabolic disorders
With its proprietary small molecule compounds, Azafaros will concentrate on new treatments for patients suffering from LSDs and LSD-related diseases. These compounds interfere with the metabolism of glycolipids that is disturbed in these patients and are intended to counteract the underlying pathological effects.
Leadership
Olivier has a very strong industry track record most recently at Idorsia Pharmaceuticals, and before that at Actelion Pharmaceuticals and Hoffmann-La Roche. Olivier brings a broad scientific, clinical and regulatory experience as well as business insights to the Azafaros team.
Recent news
Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders
Leiden, The Netherlands, July 23th, 2018 – Azafaros, a biotech company established in Leiden in the Netherlands, focusing on the development of new therapies in the field of rare metabolic disorders, today announced the closing of a seed financing round. BioGeneration...
Contact
Azafaros B.V.
Visiting address:
J.H. Oortweg 21
2333 CH Leiden
The Netherlands
Mailing address:
Gooimeer 2-35
1411 DC Naarden
The Netherlands